May 10th 2024
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
Selinexor-Based Triplet Therapy Improves Outcomes in Certain Patients with RRMM
November 24th 2023In the first article of a 2-part series, Sumit Madan, MD, discusses how the combination of selinexor, bortezomib, and dexamethasone shows superior survival outcomes for patients with relapsed/refractory multiple myeloma that are proteasome inhibitor naive or have high-risk cytogenetics.
Read More
Developing Standard Operating Procedures for Using Bispecific Agents
November 23rd 2023During a Case-Based Roundtable event, Robert Mancini, PharmD, BCOP, FHOPA, discusses his experience setting up procedures for administering bispecific T-cell engagers for a large community oncology practice. This is the first of 2 articles based on this event.
Read More
Isatuximab Combo Provides Durable Option in High-Risk Multiple Myeloma
November 20th 2023In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.
Read More
DuMontier Discusses Frailty in Newly Diagnosed Multiple Myeloma
November 18th 2023Clark DuMontier, MD, discusses the main takeaways from his presentation on treatment intensity and frailty in newly diagnosed patients with multiple myeloma given at the 20th International Myeloma Society Annual Meeting.
Watch
Clinical Pearls for Community Oncologists Treating Patients With RRMM
November 15th 2023Rafael Fonseca, MD, envisions a future where bispecific antibodies and CAR T-cell therapy, currently used in advanced stages of multiple myeloma treatment, can offer potential cure for patients, and emphasizes the importance of advocating for their broader application in community settings.
Watch
Novel Treatments and Targets Under Investigation for Patients With RRMM
November 15th 2023An expert oncologist discusses novel treatments for relapsed/refractory multiple myeloma presented at recent meetings, highlighting a study on elranatamab, a new compound targeting BCMA, and trials including the LINKER-MM1 study on linvoseltamab.
Watch
Optimal Sequencing in Patients With RRMM Previously Treated With a BCMA-Targeted Therapy
November 8th 2023Rafael Fonseca, MD, discusses the sequencing of CAR-T and bispecific antibodies in patients with relapsed/refractory multiple myeloma and tailoring treatment based on prior medical history for elderly and frail individuals.
Watch
Manageable Toxicities Allow For Flexible Treatment in RRMM
November 2nd 2023In the second article of this 2-part series, Sikander Ailawadhi, MD, discusses how understanding the safety profile of the bispecific antibody teclistamab allows for physicians to treat and monitor their patients in a better way for them.
Read More
Strategies for Risk Stratification Inform Treatment Decisions in Multiple Myeloma
November 2nd 2023The role of risk stratification in treatment decisions for patients with newly diagnosed, transplant eligible multiple myeloma vs newly diagnosed, transplant ineligible multiple myeloma was explored by Natalie S. Callander, MD.
Read More
Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM
November 1st 2023Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.
Watch
Available Treatment Options for Later Lines of Therapy in Patients With RRMM
November 1st 2023Rafael Fonseca, MD, emphasizes the considerations of selecting therapies targeting specific markers like BCMA and GPRC5D in patients with relapsed/refractory multiple myeloma, such as prior exposures, efficacy, and potential side effects.
Watch
Do Race and Ethnicity Affect Response to CAR T-Cell Therapy?
October 27th 2023While response and safety may vary across racial and ethnic subgroups, progression-free survival and overall survival does not appear to differ when chimeric antigen receptor T-cell therapy is used in the treatment of patients with multiple myeloma.
Read More
Reviewing Treatment Decisions for a 66-Year-Old Man With RRMM
October 25th 2023Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.
Watch
Future Landscape: Collaboration for Patients With Relapsed/Refractory Multiple Myeloma
October 20th 2023Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.
Watch
Choosing Between CAR T and Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
October 20th 2023David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.
Watch
Study Supports Daratumumab Use in R/R Multiple Myeloma
October 18th 2023While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.
Read More
Targeting BCMA With Teclistamab Produces Impactful Results in RRMM
October 12th 2023In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.
Read More